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Topotecan is a potent inhibitor 
of SUMOylation in glioblastoma 
multiforme and alters both 
cellular replication and metabolic 
programming
Joshua D. Bernstock  1,2, Daniel Ye 1, Florian A. Gessler 2,3, Yang-ja Lee1, Luca Peruzzotti-
Jametti 2, Peter Baumgarten4, Kory R. Johnson5, Dragan Maric6, Wei Yang  7, Donat Kögel3, 
Stefano Pluchino 2 & John M. Hallenbeck1
Protein SUMOylation is a dynamic post-translational modification shown to be involved in a diverse 
set of physiologic processes throughout the cell. SUMOylation has also been shown to play a role in the 
pathobiology of myriad cancers, one of which is glioblastoma multiforme (GBM). As such, the clinical 
significance and therapeutic utility offered via the selective control of global SUMOylation is readily 
apparent. There are, however, relatively few known/effective inhibitors of global SUMO-conjugation. 
Herein we describe the identification of topotecan as a novel inhibitor of global SUMOylation. We also 
provide evidence that inhibition of SUMOylation by topotecan is associated with reduced levels of CDK6 
and HIF-1α, as well as pronounced changes in cell cycle progression and cellular metabolism, thereby 
highlighting its putative role as an adjuvant therapy in defined GBM patient populations.
Glioblastoma multiforme (GBM) is the most common and aggressive cancer intrinsic to the brain and has there-
fore been designated by the World Health Organization (WHO) as a grade IV glioma1, 2. The diffuse infiltrative 
growth of GBM tumour cells into adjacent tissue prevents complete tumour resection, resulting in the need for 
adjuvant therapy3 consisting of combined radio- and/or chemotherapy4–6. Unfortunately, residual tumour cells 
display an intrinsic resistance against chemotherapeutic agents7, 8. Treatment of these primary brain tumours 
therefore presents a major challenge for both neurosurgery and clinical neuro-oncology, as the prognosis remains 
dismal even after maximal surgical resection of the tumour in combination with adjuvant chemoradiation.
Recent advances in the understanding of the signalling pathways that underlie GBM pathogenesis reflect 
the highly mutated genome of GBM, which is characterized by the dysregulation of many key pathways includ-
ing those involved in growth, proliferation, survival, metabolism and/or apoptosis9, 10. To address the enor-
mous complexity of such dysregulated network dynamics in GBM, a focus on plurifunctional targets that affect 
multiple pathways is prudent. One such target is global small ubiquitin-related modifier (SUMO)ylation, a 
post-translational modification (PTM) that operates in states of tolerance and acts to preserve homeostasis under 
stress11. Briefly, SUMO, like ubiquitin, is synthesized as an inactive precursor and is processed by SUMO-specific 
proteases (SENPs) to yield its mature form12. A single heterodimeric E1 enzyme, SAE1/SAE2, serves to initiate 
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conjugation by adenylating SUMO, leading to the formation of a covalent thioester E1-SUMO intermediate. 
Subsequently, SUMO is then transferred to the catalytic cysteine of the sole E2-conjugase, Ubc9, which either 
alone or in concert with a target specific E3-ligase catalyses the formation of an isopeptide linkage between the 
C-terminal glycine residue of SUMO and the ε amino group of the substrate lysine residue. SUMO conjugation 
is balanced via the deconjugative actions of the various SENPs13. There are three systemically distributed SUMO 
paralogs in mammals: SUMO-2 and SUMO-3, which are 97% identical and cannot be distinguished by specific 
antibodies; and SUMO-1, which shares only 47% homology with the other paralogs and therefore has distinct 
immunoreactivity14. SUMOylation has been documented to play a role in numerous processes throughout the 
cell, including signal transduction, gene expression, chromatin remodelling, and protein translocation14.
Beyond cellular homeostasis, evidence has emerged to support a critical role for SUMOylation in the develop-
ment and progression of numerous cancers15, 16. Considering the role SUMOylation plays in maintaining cellular 
function under states of stress/unfavourable conditions, it is not surprising that substantial evidence indicates a 
positive association between SUMOylation and cancer cell growth, tumorigenesis, metastasis, and, ultimately, 
poor patient prognosis17. Of particular interest are the recent reports that have emerged linking SUMOylation 
to the development and progression of GBM18, 19. Yang et al. demonstrated that SUMO-conjugation is activated 
in human astrocytic brain tumours, with levels of both SUMO-1 and SUMO-2/3 conjugated proteins shown 
to be markedly elevated in GBM18. Blocking SUMO-1-3 conjugation in GBM cells inhibited DNA synthesis, 
cell growth, and the clonogenic survival of GBM cells18. Further, the eloquent work of Bellail and colleagues19 
definitively demonstrated that cyclin dependent kinase (CDK)6 is modified by SUMO-1 in GBM, and that CDK6 
SUMOylation stabilizes the protein and drives the cell cycle, leading to cancer development/progression via inhi-
bition of its ubiquitin-mediated degradation. These findings collectively support the idea that the inhibition of 
SUMO-conjugation (ideally via an approved/repurposed small molecule) may provide a novel/unique strategy 
in the treatment of GBM.
The family of camptothecins currently consists of irinotecan, topotecan, and 9-aminocamptothecin20, with 
camptothecin having originally been isolated from the Chinese yew tree, Camptotheca acuminate21. Topotecan 
is a semisynthetic water-soluble derivative of the parent compound camptothecin and is approved by the Food 
and Drug Administration (FDA) for use in several cancers (e.g. cervical, ovarian, and small cell lung cancer)22, 23. 
The principal mechanism of action for this class of molecules relates to the inhibition of DNA topoisomerase I. 
Therefore, topotecan exerts the majority of its cytotoxic effects during S-phase of the cell cycle24. Given that topo-
tecan has been shown capable of modulating the SUMOylation status of its target DNA topoisomerase I25 and has 
recently been reported to have other non-canonical functions (e.g. the inhibition of hypoxia inducible factor-1 
[HIF-1α])26, we sought to explore its ability to modulate global SUMOylation in GBM.
Herein we describe topotecan’s ability to act as a novel inhibitor of global SUMOylation and its putative role as 
an adjuvant therapy in GBM treatment regimens via the inhibition of CDK6 and HIF-1α which promote changes 
in both GBM cell cycle progression and cellular metabolism.
Results
Ginkgolic and anacardic acid fail to decrease levels of protein SUMOylation in human GBM 
lines. Multiple reports have emerged to link SUMOylation, with the pathogenesis of GBM. Accordingly, the 
inhibition of SUMOylation via genetic manipulation of the pathway has been shown to be efficacious in pre-
clinical models of GBM18, 19. Herein we sought to improve upon such experiments and in so doing extend the 
translational relevance of such critical work by exploring the ability of reported small molecule inhibitors of 
SUMOylation in representative human GBM lines (i.e. U251, LN229 and Mz18). Surprisingly, we found that the 
established SUMOylation inhibitor ginkgolic acid (C15:1)/(C17:1) and its structural analog anacardic acid were 
not capable of decreasing SUMO-1 or SUMO-2/3-conjugation at either 10 µM or 100 µM concentrations (Fig. 1).
The alkylating agent temozolomide (TMZ) does not alter SUMO-conjugation in human GBM 
lines. Previous work has indicated that protein SUMOylation is altered in cells exposed to alkylating agents27. 
To further explore global SUMOylation in the context of the standard GBM chemotherapeutic regimen we exam-
ined the levels of SUMO-1 and SUMO-2/3 conjugation after exposure to the alkylating agent temozolomide 
(TMZ) at concentrations of 50 µM and 500 µM; TMZ did not decrease levels of SUMOylation at these doses. In 
fact, there was a trend towards increased conjugation of SUMO-1 that failed to reach statistical significance com-
pared to the DMSO control (Fig. 2).
Topotecan inhibits SUMO-conjugation in multiple cancer cell lines and primary rat cortical neu-
rons. In an effort to effectively target SUMOylation in a manner that would be of translational significance, 
we utilized the FDA-approved drug topotecan. Topotecan was capable of significantly decreasing the levels of 
SUMO-1 conjugation at both the 1 µM and 10 µM doses in all three human GBM lines (Fig. 3A,B and C) and 
SUMO-2/3 conjugation in all three human GBM lines at the 10 µM dose (Fig. 3A,B and C). Of note, topotecan 
was also capable of inducing a decrease in global SUMO-conjugation in human neuroblastoma SH-SY5Y cells 
and rat E18-derived primary cortical neurons at 10 µM (Fig. 3D and E). We also examined the effects of topote-
can on other PTMs: i.e. Ubiquitin Fold Modifier 1 (UFM1), Neural precursor cell Expressed Developmentally 
Downregulated-8 (NEDD8), Interferon-Stimulated Gene-15 (ISG15), and Fau Ubiquitin-like protein (FUB1). 
NEDDylation was decreased by topotecan in lines U251 and LN229 but was unaltered in Mz18 (Supplemental 
Figs 1A, 2A and 3A). The levels of FUB1, UFM1 and ISG15 conjugation did not change after treatment with 
topotecan in lines U251 (Supplemental Fig. 1B,C and D), LN229 (Supplemental Fig. 2B,C and D) or Mz18 
(Supplemental Fig. 3B,C and D). Of note, the mechanism by which topotecan inhibits SUMOylation is unlikely 
to involve the levels of the conserved E1 (SAE1/SAE2) or E2 (Ubc9) components of the pathway as these proteins 
were unaffected after exposure to topotecan (Supplemental Fig. 4).
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Topotecan leads to perturbations in both cell cycle and metabolic profiles of human GBM 
cell lines. We also observed that topotecan reduced the levels of the cell cycle protein CDK6 (Fig. 4A). This 
decrease is in line with reports by Bellail et al.19, which demonstrated that CDK6 stability/protection from the 
proteasome in GBM was dependent on SUMOylation. The addition of the 26S proteasome inhibitor MG132 
blocked topotecan mediated CDK6 degradation (Fig. 4B). Furthermore, we conducted immunoprecipitation (IP) 
experiments in which CDK6 was pulled-down and probed with a polyclonal anti-SUMO1 antibody. Significantly 
less SUMO-1 was conjugated to CDK6 in GBM cells treated with topotecan (Fig. 4C). Cell cycle analysis revealed 
a G1/S transition block in GBM cells treated with topotecan in the absence of a major sub-G1 cell fraction indic-
ative of apoptosis. However, topotecan proved to be additive in terms of cellular cytotoxicity in combination with 
TMZ at 72hrs in the TMZ-resistant line LN22928 (Supplemental Fig. 5). Of note, at both the concentrations/
times used throughout this study, topotecan does not appear to act solely via inhibition of topoisomerase I23, 
as no significant arrest at the G2/M checkpoint of the cell cycle was observed during fluorescence-activated cell 
sorting (FACS) analysis (Fig. 5A,B and C). Figure 5D highlights the proposed mechanism of action of topotecan 
with regard to the CDK6 axis. In an effort to delineate the identity of other proteins which are SUMOylated in 
GBM we performed global SUMO-1 IPs and subjected those proteins that were pulled-down to liquid chroma-
tography (LC)/mass spectrometry (MS)/MS analysis. The target identification results obtained using line U251 
suggested that perturbation of SUMOylation may affect cellular metabolism, which is supported by the literature 
(Fig. 6A)29, 30. Appropriately, both the pentose phosphate pathway and glycolytic metabolism were altered fol-
lowing treatment with topotecan, as suggested by a reduction in lactate levels (Fig. 6B) and glucose-6-phosphate 
Figure 1. Ginkgolic and anacardic acid fail to suppress global SUMO-conjugation in human GBM lines. U251 
(A), LN229 (B), and Mz18 (C), at concentrations of 10 μM or 100 μM. Representative immunoblots are shown. 
High molecular weight (>100 kDa) SUMO-1 and SUMO-2/3 conjugates were cropped in each lane and the total 
intensities were measured. Densitometries were normalized to corresponding actin levels and expressed as a 
fold difference relative to the control (DMSO). Data are means (±SD) from n = 3 independent experiments.
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dehydrogenase (G6PD) activity (Fig. 6C). Critically, these results are likely to be related to the dose-dependent 
decreases identified in HIF-1α after treatment with topotecan in all three GBM lines examined (Fig. 6D).
Immunohistochemistry (IHC) of surgically resected tumour samples reveals differential levels 
of SUMOylation between GBM patients. Having shown that topotecan is able to target SUMOylation in 
Figure 2. Temozolomide does not decrease global levels of SUMO-conjugation in human GBM lines. U251 
(A), LN229 (B), and Mz18 (C), at concentrations of 50 μM and 500 μM. Representative immunoblots are shown. 
High molecular weight (>100 kDa) SUMO-1 and SUMO-2/3 conjugates were cropped in each lane and the total 
intensities were measured. Densitometries were normalized to corresponding actin levels and expressed as a 
fold difference relative to the control (DMSO). Data are means (±SD) from n = 3 independent experiments.
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a manner that would be of translational importance we sought to extend our findings by confirming the presence 
of elevated levels of global SUMOylation within certain subpopulations of GBM patients. Accordingly, immuno-
histochemistry (IHC) for SUMO-1 was performed using samples from 10 GBM patients. Figure 7A represents 
staining deemed to be minor (2 patients); Fig. 7B represents staining deemed to be moderate (3 patients); Fig. 7C 
represents staining deemed to be intense (5 patients). Figure 7D confirms that SUMO-1 was detectable in all 
samples analysed. IHC for SUMO-2/3 expression in GBM was also performed in the same 10 GBM patients. 
Figure 7E represents staining deemed to be minor (3 patients); Fig. 7F represents staining deemed to be moderate 
(6 patients); Fig. 7G represents staining deemed to be intense (1 patients). Figure 7H confirms that SUMO-2/3 
was detectable in all samples analysed.
Discussion
Therapeutic options for the treatment of GBM are limited, and despite years of focused research GBM patient 
prognosis remains dismal. Accordingly, herein we describe the ability of the FDA approved drug topotecan to act 
as a novel inhibitor of global SUMOylation, as well as its putative role as an adjuvant therapy in GBM treatment 
regimens via the inhibition of global SUMOylation, CDK6, and HIF-1α.
Figure 3. Topotecan causes a decrease in the levels of SUMOylated proteins in GBM, neuroblastoma and 
E18 primary cortical neurons. U251 (A), LN229 (B), and Mz18 (C) at concentrations of 1 μM and 10 μM, 
and neuroblastoma line SH-SY5Y (D) and rat E18 primary cortical neurons (E) at 10 μM. Representative 
immunoblots are shown. High molecular weight (>100 kDa) SUMO-1 and SUMO-2/3 conjugates were cropped 
in each lane and the total intensities were measured. Densitometries were normalized to corresponding actin 
levels and expressed as a fold difference relative to the control (DMSO). Data are means (±SD) from n = 3 
independent experiments. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 vs. DMSO.
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Critically, dysregulation of SUMOylation has been reported to be involved in tumorigenesis19, 31–33; the role 
of SUMOylation in the majority of cancers appears to be related to an upregulation of the pathway, although 
downregulations have been described15, 33. Therefore, the therapeutic targeting of protein SUMOylation may 
represent a novel approach for the treatment of myriad cancers, including GBM; interestingly recent reports 
have also emerged demonstrating that elevations in the conjugation of NEDD8 are involved in the pathogenesis 
of GBM34. In human astrocytic brain tumours, SUMO1–3 conjugation has been shown to be elevated and is 
required for glioblastoma cell survival18; it also serves to modify/stabilize CDK619. Notwithstanding the impor-
tance of SUMOylation in regulating diverse biological systems and diseases, only a few small molecule inhibitors 
of SUMOylation have been reported to date, notably ginkgolic acid and its analog anacardic acid35. As such, we 
analysed these previously reported inhibitors of protein SUMOylation in three different human GBM cell lines. 
Figure 4. Topotecan alters CDK6 levels in GBM lines. (A) Topotecan causes a decrease in CDK6 protein levels 
in GBM lines U251, LN229, and Mz18 at concentrations of 1 μM and 10 μM. (B) The addition of MG132, a 
specific inhibitor of the protease activity of the 26S complex, attenuates the decrease in CDK6 protein levels 
previously seen in lines U251 and LN229. Representative immunoblots are shown. The band corresponding to 
CDK6 (40 kDa) was cropped in each lane and the total intensities were measured. Densities were normalized 
to corresponding actin levels and expressed as a fold difference relative to the control (DMSO). Data are means 
(±SD) from n = 5 independent experiments. **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 vs. DMSO. (C) Lysates 
from U251 cells treated either with DMSO or topotecan at 1 μM for 12hr were immunoprecipitated using 
an anti-CDK6 antibody followed by immunoblotting using an anti-SUMO-1 antibody. Arrow highlights the 
predicted CDK6-SUMO-1 band.
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While others have reported decreases in protein SUMOylation using ginkgolic/anacardic acid in various models 
of cancer (e.g. breast, colorectal and pancreatic), the literature lacks reports on the preclinical efficacy of ginkgo-
lic/anacardic acid in GBM36, 37. Incubation of GBM tumour cell lines with ginkgolic acid or anacardic acid did 
not result in statistically significant decreases in global protein SUMOylation; whether this may be attributed to 
exceptionally high levels of global SUMOylation in GBM cells of up to ~40-fold of that of normal tissue18, the 
employment of different dosing stratagems and/or some other unique feature of GBM pathobiology remains to 
be elucidated.
While the camptothecin derivative topotecan continues to be evaluated as a treatment for GBM in ongoing 
clinical studies (e.g. ClinicalTrials.gov Identifiers: NCT01931098, NCT01004874 NCT00638898), its ability to 
inhibit SUMOylation has yet to be explored. Here we have demonstrated that topotecan decreases the levels of 
global SUMOylation in both human GBM and neuroblastoma cell lines. We have also shown that topotecan is 
capable of inducing a decrease in the levels of global SUMOylation in E18 rat primary cortical neurons, suggest-
ing that the observed changes are not to be solely attributed to the inhibition of topoisomerase I, as differentiated 
cortical neurons are quiescent (i.e. remaining within the G0 phase of the cell cycle). Critically the reductions in 
SUMOylation noted throughout the course of this study do not appear to involve the levels of E1/E2 enzymes 
(SAE1/SAE2 and Ubc9 respectively). Additional work will therefore be required to examine the activity of Ubc9, 
E3-target specific ligases and/or relevant SENPs after exposure to topotecan in an effort to further elucidate the 
governing mechanisms of action.
In line with such findings we also observed a concordant decrease in CDK6 levels and alterations in the 
cell cycle of all three GBM lines examined confirming previous work which has highlighted the role of 
Figure 5. Topotecan alters the cell cycle in GBM lines effecting a decrease in S-phase progression in U251 
(A), LN229 (B), and Mz18 (C) and an increase in G0/G1-phase restriction in U251 (A). FACS was used to 
determine the phase of the cell cycle via the incorporation of 5-ethynyl-2′-deoxyuridine (EdU). Data are means 
(±SD) from n = 3 independent experiments. **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 vs. DMSO. (D) Putative 
mechanism by which topotecan perturbs the CDK6 axis and cell cycle progression at the 1 μM and 10 μM doses.
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Figure 6. Topotecan alters the proteomic/metabolic profile of GBM cell lines and decreases the levels of 
HIF-1α. (A) Global SUMO-1 pull-down in line U251, probed with an anti-SUMO-1 antibody. D = DMSO 
(0.1%), T = Topotecan 1 μM. Input = precleared lysate, IP = immunoprecipitated lysate. Mass spectrometry 
detected 82 proteins co-immunoprecipitated with SUMO-1 in only the DMSO control condition, 20 proteins in 
only the topotecan condition, and 97 proteins in both conditions. The top 10 attenuated pathways and functions 
in topotecan-treated cells based on mass spectrometry results are reported; Fisher’s Exact Test was used to assess 
significance; x-axes represent the −log(enrichment P-value). (B) Levels of lactate, a by-product of glycolysis, 
decreases in a dose-dependent manner with topotecan treatment in lines U251, LN229, and Mz18. (C) Activity 
of glucose-6-phosphate dehydrogenase, an enzyme in the pentose phosphate pathway, decreases in a dose-
dependent manner with topotecan treatment in lines U251, LN229, and Mz18. (D) Topotecan effects a dose-
dependent decrease on levels of HIF-1α protein in GBM lines U251, LN229, and Mz18 at concentrations of 
1 μM and 10 μM. Representative immunoblots are shown. The bands corresponding to HIF-1α (~116 kDa) were 
cropped in each lane and the total intensities were measured. Densities were normalized to corresponding actin 
levels and expressed as a fold difference relative to the control (DMSO). Data in B-D are means (±SD) from 
n = 3 independent experiments. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 vs. DMSO.
www.nature.com/scientificreports/
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SUMO1–conjugation in CDK6 stability/cell cycle progression in GBM19. By inducing CDK6 degradation via the 
inhibition of SUMO1-conjugation, topotecan may ultimately enhance the therapeutic efficacy of CDK4/6 kinase 
inhibitors such as PD0332991 (i.e. palbociclib), which have already displayed promising results in GBM38. Such 
a finding would echo the conclusions put forth by Hamilton et al.39 in drug-resistant small cell lung cancer, in 
which they highlight the synergism of CDK inhibitors with camptothecin derivatives, albeit without a definitive 
mechanism.
Figure 7. Immunohistochemistry (IHC) reveals different patterns of global SUMOylation between GBM 
patients. Immunohistochemistry for SUMO-1 and SUMO-2/3 was visualized using 3,3′-diaminobenzidine 
(DAB) and counterstained with hematoxylin (blue). SUMO-1 expression in GBM showing minor (A), 
moderate (B) or intense (C) expression. (D) Neuropathological scoring of SUMO-1 expression in 10 GBM 
patients. SUMO-2/3 expression in GBM showing minor (E), moderate (F) or intense (G) expression. (H) 
Neuropathological scoring of SUMO-2/3 expression in 10 GBM patients. Scale bars indicate 200 µm. Images 
were taken at 10x magnification with enlarged panels representing 40x magnification.
www.nature.com/scientificreports/
1 0SCIENTIFIC REPORTS | 7: 7425  | DOI:10.1038/s41598-017-07631-9
It is perhaps unsurprising that novel mechanisms for topotecan exist as other recent reports have shown that 
topotecan is capable of inhibiting the transcription factor HIF-1α26, 40 which is a key driver of GBM tumour pro-
gression/therapeutic resistance41. Of note, HIF-1α can be SUMOylated and hypoxia is capable of influencing this 
process42–47. It should be noted that controversy exists regarding the underlying cellular mechanisms/outcomes of 
HIF-1α SUMOylation. Some reports have claimed that SUMOylation stabilizes HIF-1α and in so doing enhances 
its transcriptional activity, while other reports have claimed that hypoxia-induced HIF-1α SUMOylation neg-
atively regulates its stability and transactivation43, 45, 46, 48–51. Here we have shown that topotecan is capable of 
decreasing HIF-1α levels in all GBM cell lines examined. HIF-1α induces the expression of genes encoding pro-
teins that enable cell survival in hypoxic conditions via an induction of glycolytic enzymes and growth factors (e.g. 
vascular endothelial growth factor [VEGF] and erythropoietin) that increase vascular supply to the tumour and 
is therefore a critical oncotarget40. Further, HIF-1α has been linked to the expression of epithelial-mesenchymal 
transition (EMT)-associated proteins in GBM52 with EMT itself having shown to be driven primarily by a tran-
scriptional profile controlled via SUMOylation16. With regard to cellular metabolism it is important to note that 
GBM displays a unique bioenergetic state of aerobic glycolysis known as the “Warburg effect”53, 54. Accordingly, 
reports have emerged which have come to suggest that targeting the Warburg shift may represent a novel thera-
peutic approach for the treatment of GBM55–57. Again, both SUMOylation and HIF-1α have been shown to play 
definite roles in a switch to glycolysis in states of both health and disease29, 30, 58, 59. Topotecan’s ability to target 
both of these axes speaks to its potential as an adjuvant therapy within hypoxic tumour microenvironments and 
immediately suggests potential synergy with anti-angiogenetic and/or metabolic therapies.
It is prudent to note that topotecan and other camptothecin derivatives have undergone clinical trials in GBM 
patient cohorts and thus far have displayed limited efficacy60–65. As per the differential staining demonstrated 
upon IHC varying levels of both SUMO-1 and SUMO-2/3 expression exist within GBM patients. To this end, 
it remains to be determined whether those patients demonstrating a response to topotecan treatment do in fact 
have elevated levels of SUMOylation. Beyond topotecan, combinations of irinotecan and temozolomide have 
been examined and appear to display some beneficial effects66, 67. Interestingly, a recently published trial which 
employed a combination therapy centred on bevacuzimab (i.e. a humanized anti-VEGF monoclonal antibody) 
and irinotecan resulted in a superior progression free survival (PFS) rate and median PFS as compared with 
temozolomide68. Such a finding speaks to the potential synergy of camptothecin derivatives in combination with 
antiangiogenic therapies with the understanding that both SUMOylation and HIF-1α directly contribute to 
hypoxic stress responses.
Conclusions
Topotecan decreases the levels of global SUMO-conjugation, CDK6, and HIF-1α in GBM cells thereby altering 
both the cell cycle and metabolic profile. Our findings therefore suggest a novel mechanism of action for topote-
can and a therapeutic role for the drug in GBM and other cancers, which have hijacked the SUMOylation process 
(with the understanding that topotecan has FDA approval for the treatment of ovarian, cervical, and small cell 
lung cancers). It is therefore the authors’ contention that the repositioning of topotecan as an adjuvant therapy in 
GBM may ultimately lead to improved outcomes in defined cohorts of patients.
Materials and Methods
Small molecules. All small molecules (topotecan, anacardic acid, ginkgolic acid, temozolomide, MG132) 
were purchased from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO) and stock solutions were made in dimethyl 
sulfoxide (DMSO). All dilutions resulted in a final concentration of 0.1% DMSO within the growth media.
Cell culture isolation of primary cortical neurons. The human GBM cell lines (U251, LN229, Mz18) 
and human neuroblastoma cell line (SH-SY5Y) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Life Technologies, Grand Island, NY) supplemented with 10% heat-inactivated foetal bovine serum (FBS) 
(Atlanta Biologicals Inc., Flowery Branch, GA), 100 U/mL penicillin, and 100 mg/mL streptomycin in 5% CO2 
at 37 °C. Animal experiments were approved by the NIH/NINDS ACUC (Animal Care and Use Committee): 
cortical neurons were isolated from E18 embryos of Sprague-Dawley rats in accordance with the policies set 
forth by the ACUC of the NINDS (ASP #1225–14). Further, all experiments utilizing these cells were performed 
in accordance with NINDS/NIH and ACUC guidelines. Briefly, cortices were dissected from the embryos, dis-
sociated with papain (Worthington Biochemicals, Lakewood, NJ), and plated out at 1,000,000 cells per well on 
poly-L-lysine-coated 6 well plates in Neurobasal-A/B27 (Life Technologies) media as described previously69. 
Cortical neurons were used after 7–10 days in culture.
GBM patient tissue microarray (TMA). Formalin-fixed, paraffin-embedded tissue samples of 10 GBM 
patients originally diagnosed between 2007–2009 were retrieved from the archives of the Edinger Neurological 
Institute as part of a Tissue MicroArray (TMA)70. Of note, all samples were reviewed by at least two board certi-
fied neuropathologists according to the WHO criteria for CNS tumours.
Cell cycle analysis. 350,000 GBM cells/well were plated into 6-well plates and allowed to attach before being 
treated with topotecan in 0.1% DMSO for 12 hrs. Cells were lifted, fixed, permeabilized, and stained using the 
Click-iT EdU Plus Flow Cytometry Assay Kit (Thermo Fisher Scientific, Waltham, MA) as per the manufacturer’s 
instructions. This was followed by counterstaining with 4′,6-diamidino-2-phenylindole (DAPI) to assay total 
DNA content per cell. Cells were then analysed by flow cytometry using a MoFlo Astrios cell sorter with Summit 
Acquisition software (Beckman Coulter, Indianapolis IN); 50,000 events were acquired per sample. Data analysis 
was completed with Kaluza software (Beckman Coulter).
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Immunoprecipitation and Western blot analyses. After removal of the treated media and wash-
ing with phosphate buffered saline (PBS), cells were lysed in an IP buffer which contained (50 mM HEPES pH 
7.3, 100 mM NaCl, 1.5 mM MgCl2, 1% NP40, 0.1% SDS, 1 mM PMSF, 20 mM NEM, MS-SAFE protease/phos-
phatase inhibitor cocktail). The cell lysates were then incubated for 1 hr on ice and then centrifuged for 20 min 
at ~12,000 × g at 4 °C. After pre-clearing with Dynabeads Protein G (Thermo Fisher Scientific), protein con-
centrations were measured via a Pierce BCA Protein Assay (Thermo Fisher Scientific). Equal amounts of pro-
tein amongst the relevant samples were ultimately used for IP. After incubation with the primary antibody for 
2 hr at 4 °C, Dynabeads Protein G was added and incubated overnight at 4 °C. The washing and eluting of IP 
products that followed conformed entirely to the manufacturer’s (Thermo Fisher Scientific) protocol. Total cell 
lysates for Western blots from SHSY5Y, B35, or E18 primary cortical neurons were prepared as has been previ-
ously described11, 47. The antibodies used throughout the course of this study were as follows: rabbit polyclonal 
anti-SUMO-1 and anti-SUMO-2/3 (both developed in-house); anti-SAE1, anti-SAE2, anti-Ubc9, anti-UFM1, 
and anti-ISG15 (Abcam, Cambridge, MA); anti-NEDD8 (Cell Signaling Technology, Danvers, MA); anti-FUB1 
(Abnova, Taipei, Taiwan); anti-CDK6 and anti-HIF-1α (Santa Cruz Biotechnology, Dallas, TX); and anti-β-actin 
(Sigma-Aldrich). Protein expression levels were determined via densitometric analysis of the corresponding pro-
tein bands of interest using ImageJ (NIH, Bethesda, MD). In order to measure SUMO-conjugation levels, regions 
corresponding to molecular weights above 100 kDa in each lane were cropped and the total intensity analysed. 
Other PTMs were analysed as previously described71. All densities were normalized to the corresponding actin 
levels and expressed as the ratio to control (DMSO alone).
Immunohistochemistry. Tumour sections (3 µm) were subjected to IHC for SUMO-1 and SUMO-2/3 
(antibodies: in-house rabbit polyclonals, dilutions 1:50). Tissue labelling for all antigens was performed using 
DiscoveryXT IHC system (Ventana, Strasbourg, France) via standardized protocols as has been previously pub-
lished70. Imaging was performed using an Olympus BX50 light microscope (Olympus, Hamburg, Germany). 
Intensity was quantified independently by two authors as either “not detectable; minor; moderate; intense”.
Proteomic identification (LC/MS/MS) and biological function and pathway enrichment anal-
ysis. Protein identification of excised Coomassie Blue-stained gel bands was performed by in-gel tryp-
tic digestion, analysis of the resulting digest by LC/MS/MS, and database searching as described previously72. 
MS-identified proteins for two separate SUMO-1 pull-down fractions representing DMSO treatment and TOPO 
treatment were filtered to keep proteins having at least 2 significant peptide matches. For these proteins, three lists 
were organized by symbol: detected in both the DMSO and TOPO fractions (n = 97), detected in the DMSO frac-
tion only (n = 82), and detected in the TOPO fraction only (n = 20). For proteins detected in the DMSO fraction 
only, symbols were imported into Ingenuity Pathway Analysis (IPA) (www.ingenuity.com) and the corresponding 
enriched functions and pathways identified.
Lactate levels assays. Cell media were harvested/centrifuged at ~1750 × g after incubation with topotecan 
for 12 hrs. Samples were subsequently incubated at 99 °C for 10 min to remove the confounding effects of lactate 
dehydrogenase present within the media/FBS. The lactate fluorometric assay kit was carried out according to the 
manufacturer’s instructions (BioVision, Milpitas, CA).
Glucose-6-phosphate dehydrogenase assay. Cells in 10-cm tissue culture plates were treated for 12 hrs 
with DMSO or topotecan (1 and 10 μM at 0.1% DMSO total volume). After removal of the treated media and 
washing with PBS, cells were lysed in IP lysis buffer (as per the above) and kept on ice for 1 hr with intermittent 
inversion. Lysates were then centrifuged at ~12000 × g for 20 min at 4 °C and the pellet was discarded. BCA pro-
tein quantitation was used to normalize the amount of protein between samples. The glucose-6-phosphate dehy-
drogenase activity colorimetric assay kit was carried out according to the manufacturer’s instructions (BioVision).
Lactate dehydrogenase cytotoxicity assay. Cells were seeded at a density of 200,000 cells/well into 
6-well plates and allowed to grow overnight (O/N). Cells were then incubated in media containing increasing 
doses of TMZ, topotecan, or both at a final concentration of 0.1% DMSO. Readouts were performed at 12 and 72 
hrs as per the manufacturer’s directions (LDH Cytotoxicity Kit, Abcam).
Statistical analysis. To test for differences in treatments (e.g. topotecan) vs control (DMSO), ANOVA (one 
or two-way) followed by post-hoc testing (Dunnett’s or Bonferroni’s respectively), was performed. Values of 
p ≤ 0.05 were deemed to be significant.
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